MedPath

Dosimetric Planning Study Comparing Intensity Modulated Radiotherapy (IMRT) and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix

Early Phase 1
Completed
Conditions
Cervix Cancer
Interventions
Radiation: IMRT planning
Radiation: 4-Field Radiation Planning
Registration Number
NCT00981552
Lead Sponsor
Sunnybrook Health Sciences Centre
Brief Summary

A theoretical planning study to compare the normal tissue irradiation when using intensity modulated radiotherapy (IMRT) as opposed to standard radiotherapy for the definitive treatment of cervical cancer.

Detailed Description

Radiotherapy in combination with chemotherapy is the standard treatment of locally advanced cervix cancer, however with traditional techniques large volumes of bowel and bladder are irradiated causing short-term and long-term genito-urinary and gastro-intestinal side effects. IMRT has the potential to conform precisely to the target and spare normal tissues and reduce side effects. However because there are large dose gradients there is the potential to miss the target due to organ motion. Recent studies have documented organ motion and will be used to define the target. Approximately 60 planning scans, previously used to treat patients with cervix cancer, will be used to replan using an IMRT technique and differences in doses to tumour and normal tissues compared.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
55
Inclusion Criteria
  • last 60 patients treated definitively for cervical cancer at Sunnybrook Odette Cancer Centre
Exclusion Criteria
  • no imaging and no anatomical description of disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cervix CancerIMRT planningPatients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
Cervix Cancer4-Field Radiation PlanningPatients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
Primary Outcome Measures
NameTimeMethod
Reduction in dose to organs at risk6 months
Secondary Outcome Measures
NameTimeMethod
Target Coverage6 months

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath